Yuan X B, Yuan Y B, Jiang W, et al. Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation[J]. Int J Pharm, 2008, 349(1/2): 241-248. [2]Vail A, Gore S M, Bradley B A, et al. Conclusions of the corneal transplant follow up study. Collaborating Surgeons[J]. Br J Ophthalmol, 1997, 81(8): 631-636. [3]Williams K A, Esterman A J, Bartlett C, et al. How effective is penetrating corneal transplantation? Factors influencing long-term outcome in multivariate analysis[J]. Transplantation, 2006, 81(6):？ 896- 901. [4]Xiao H, Zhang H, Yu Z Y, et al. J2 prolongs the corneal allograft survival through inhibition of the CD4+ T cell-mediated response in vivo[J]. Transpl Immunol, 2007, 18(2): 130-137. [5]Jia Z, Jiao C, Zhao S, et al. Immunomodulatory effects of mesenchymal stem cells in a rat corneal allograft rejection model[J]. Exp Eye Res, 2012, 102: 44-49. [6]Cheikhelard A, Go S, Canioni D, et al. Enhanced in situ expression of NF-kappaBp65 is an early marker of intestinal graft rejection in rats[J]. J Pediatr Surg, 2005, 40(9): 1420-1427. [7]Wuest T Y, Willette-Brown J, Durum S K, et al. The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells[J]. J Leukoc Biol, 2008, 84(4): 973-980. [8]Lee H M, Bautista J L, Hsieh C S. Thymic and peripheral differentiation of regulatory T cells[J]. Adv Immunol, 2011, 112: 25-71. [9]Cheung K W, Sze D M, Chan W K, et al. Brazilian green propolis and its constituent, Artepillin C inhibits allogeneic activated human CD4 T cells expansion and activation[J]. J Ethnopharmacol, 2011, 138(2): 463-471. [10]Williams K A, Coster D J. Penetrating corneal transplantation in the inbred rat:？ a new model[J]. Invest Ophthalmol Vis Sci, 1985, 26(1): 23-30. [11]Larkin D F, Calder V L, Lightman S L. Identification and characterization of cells infiltrating the graft and aqueous humour in rat corneal allograft rejection[J]. Clin Exp Immunol, 1997, 107(2): 381-391. [12]Coster D J, Williams K A. The impact of corneal allograft rejection on the long-term outcome of corneal transplantation[J]. Am J Ophthalmol, 2005, 140(6): 1112-1122. [13]李素霞, 谢立信. 我国眼库现状调查[J]. 中华眼科杂志, 2011, 47(9):？ 837-840. [14]王丽超, 周伟. 高危角膜移植排斥反应的预防和治疗进展[J]. 国际眼科杂志, 2014, 14(8): 1413-1416. [15]Holland E J, Chan C C, Wetzig R P, et al. Clinical and immunohistologic studies of corneal rejection in the rat penetrating keratoplasty model[J]. Cornea, 1991, 10(5): 374-380. [16]Jirasiritham S, Sumethkul V, Mavichak V, et al. The role of anti-IL-2 receptor in high-risk kidney transplant patients[J]. Transplant Proc, 2004, 36(7): 2110-2112. [17]Mohan R R, Tovey J C, Sharma A, et al. Gene therapy in the cornea:？ 2005--present[J]. Prog Retin Eye Res, 2012, 31(1): 43-64. [18]Ritter T, Yang J, Dannowski H, et al. Effects of interleukin-12p40 gene transfer on rat corneal allograft survival[J].Transpl Immunol, 2007, 18(2):？ 101-107. [19]Nashan B, Schwinzer R, Schlitt H J, et al. Immunological effects of the anti-lL-2 receptor monoclonal antibody BT 563 in liver allografted patients[J]. Transpl Immunol, 1995, 3(3): 203-211. [20]Hire K, Ngo D K, Stewart-Maynard K M, et al. FoxP3？+, and not CD25？+, T cells increase post-transplant in islet allotransplant recipients following anti-CD25？+ rATG immunotherapy[J]. Cell Immunol, 2012, 274(1/2): 83-88. ？
